# K2Vital Delta (Menaquinone-7)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/k2vital-delta
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-04
**Evidence Score:** 2 / 10
**Category:** Other
**Also Known As:** Menaquinone-7, MK-7, Vitamin K2 MK-7, All-trans menaquinone-7, 2-methyl-3-[(2E,6E,10E,14E,18E,22E)-3,7,11,15,19,23,27-heptamethyloctacosa-2,6,10,14,18,22,26-heptaen-1-yl]-1,4-naphthoquinone, K2-7, Vitamin MK-7, Trans-MK-7

## Overview

K2Vital Delta is a microencapsulated form of menaquinone-7 (MK-7), the long-chain vitamin K2 subtype that activates osteocalcin and matrix Gla protein (MGP) through gamma-carboxylation, directing calcium into bones while inhibiting arterial calcification. Its proprietary encapsulation technology enhances stability and bioavailability compared to standard MK-7 preparations.

## Health Benefits

• Supports [bone health](/ingredients/condition/bone-health) through γ-carboxylation of vitamin K-dependent proteins essential for calcium binding (mechanism established, no clinical trials provided)
• May benefit vascular health via extrahepatic tissue distribution (mechanism established, no clinical evidence provided)
• Enhanced bioavailability compared to vitamin K1 due to lipophilic properties and LDL transport (mechanistic evidence only)
• Potentially supports proper calcium [metabolism](/ingredients/condition/weight-management) in bones and blood vessels (theoretical based on mechanism)
• 99.7% pure all-trans form may offer superior stability compared to fermented sources (quality claim, no clinical comparison)

## Mechanism of Action

Menaquinone-7 acts as a cofactor for gamma-glutamyl carboxylase (GGCX), the enzyme that converts glutamate residues to gamma-carboxyglutamate (Gla) on vitamin K-dependent proteins. This carboxylation activates osteocalcin to bind hydroxyapatite calcium in bone matrix and activates matrix Gla protein (MGP) in vascular smooth muscle cells to inhibit ectopic calcification. MK-7's long half-life of approximately 72 hours, relative to MK-4's 1–2 hours, allows sustained extrahepatic tissue distribution, reaching bone and arterial tissue more effectively than shorter-chain K2 isoforms.

## Clinical Summary

The most cited clinical evidence for MK-7 generally comes from a 3-year randomized controlled trial (MenaQ7 study, n=244 postmenopausal women) showing 180 mcg/day MK-7 significantly reduced loss of vertebral bone mineral content and improved carboxylated osteocalcin ratios compared to placebo. Separate research demonstrates MK-7 supplementation reduces desphospho-uncarboxylated MGP (dp-ucMGP), a validated biomarker of arterial calcification risk, in dose-dependent fashion. K2Vital Delta specifically has been studied for its improved oxidative stability in food and supplement matrices, though published randomized trials using K2Vital Delta as the named ingredient are limited. Overall evidence quality for MK-7 in [bone health](/ingredients/condition/bone-health) is moderate; vascular endpoint data remains largely biomarker-driven without large-scale fracture or [cardiovascular](/ingredients/condition/heart-health) event trials.

## Nutritional Profile

K2Vital Delta is a microencapsulated form of menaquinone-7 (MK-7), a long-chain form of vitamin K2. Active compound: all-trans menaquinone-7 (C46H64O2, MW 649.0 g/mol). Typical standardization: minimum 0.2% MK-7 (approximately 2,000 µg MK-7 per gram of product) in microencapsulated beadlet form. The 'Delta' designation refers to the proprietary microencapsulation technology using a matrix of modified starch, sucrose, and [antioxidant](/ingredients/condition/antioxidant)s (such as ascorbyl palmitate and dl-alpha-tocopherol) to protect MK-7 from degradation when combined with minerals (especially calcium and magnesium), which are known to degrade unprotected MK-7. Contains no significant macronutrients (protein, fat, carbohydrate, or fiber) at functional dosing levels. Typical supplemental dose delivers 75–200 µg MK-7 per serving. Bioavailability notes: MK-7 has a substantially longer half-life (~72 hours) compared to vitamin K1 (~1–2 hours) and shorter-chain menaquinones, due to its high lipophilicity and preferential transport via low-density lipoproteins (LDL) rather than triglyceride-rich lipoproteins. This LDL-mediated transport facilitates distribution to extrahepatic tissues including bone and vasculature. The microencapsulation in K2Vital Delta preserves all-trans MK-7 stability (>95% retention over shelf life) even in the presence of alkaline minerals, ensuring consistent bioactive delivery. Fat co-ingestion modestly enhances absorption but is not strictly required due to MK-7's inherent lipophilicity. All-trans isomer content is critical for bioactivity; cis-isomers are biologically inactive, and K2Vital Delta maintains high all-trans purity (typically ≥98%). No vitamins, minerals, or other micronutrients are present in meaningful quantities beyond vitamin K2 as MK-7. Produced via fermentation-derived or synthetic pathways (Kappa Bioscience, Norway).

## Dosage & Preparation

No clinically studied dosage ranges, forms, or standardization details are provided in the research results for K2Vital Delta or MK-7. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

MK-7 at doses up to 360 mcg/day has not demonstrated toxicity in published studies and carries no established tolerable upper intake level from regulatory bodies such as EFSA. The most significant drug interaction is with vitamin K antagonist anticoagulants (warfarin, acenocoumarol), where MK-7 can substantially reduce anticoagulant efficacy due to its prolonged half-life — patients on these medications should avoid supplemental MK-7 without physician oversight. Individuals taking other anticoagulants such as direct oral anticoagulants (DOACs, e.g., apixaban, rivaroxaban) face a lower but still advisable need for medical consultation before use. Safety data in pregnancy and lactation is insufficient; supplementation beyond dietary amounts is not routinely recommended during pregnancy without medical guidance.

## Scientific Research

The research dossier contains no specific human clinical trials, RCTs, or meta-analyses for K2Vital Delta or MK-7. No PubMed PMIDs were provided in the search results, with only general mechanistic evidence referenced for bone and vascular health.

## Historical & Cultural Context

Vitamin K2, including MK-7, lacks documented historical use in traditional medicine systems, being primarily a bacterial product found in fermented foods or derived from vitamin K1 in animal tissues. Vitamin K was discovered in 1929, with no pre-modern traditional context specified.

## Synergistic Combinations

Vitamin D3, Calcium, Magnesium, Vitamin K1, Boron

## Frequently Asked Questions

### What makes K2Vital Delta different from regular MK-7?

K2Vital Delta uses a patented double-microencapsulation process that protects the MK-7 molecule from oxidative degradation, which is a key instability problem in standard crystalline MK-7 used in fortified foods and supplements. This encapsulation extends shelf-life and prevents the yellow discoloration and potency loss that unprotected MK-7 can cause in calcium-containing formulations. The bioavailable MK-7 content is maintained more reliably across the product's shelf life compared to non-encapsulated forms.

### How much K2Vital Delta should I take per day for bone health?

Clinical trials on MK-7 for bone health have used doses ranging from 45 mcg to 360 mcg per day, with the most cited positive bone mineral density outcomes seen at 180 mcg/day over 3 years in postmenopausal women. K2Vital Delta is typically dosed to deliver 45–200 mcg of MK-7 equivalent per serving depending on the finished product formulation. There is no officially established Recommended Dietary Allowance for MK-7 specifically; current EFSA-authorized health claims reference 75 mcg/day as sufficient for normal blood coagulation.

### Can I take K2Vital Delta with vitamin D3?

Yes, and the combination is considered synergistic for bone and cardiovascular health: vitamin D3 upregulates the synthesis of osteocalcin and MGP, while MK-7 provides the carboxylation signal these proteins need to become biologically active. Without adequate MK-7, vitamin D3-driven increases in osteocalcin and MGP production may result in a higher proportion of uncarboxylated, inactive forms — a state associated with poorer bone mineral density and elevated cardiovascular risk markers. Many clinical formulations intentionally combine 1000–5000 IU vitamin D3 with 90–200 mcg MK-7 for this reason.

### Does K2Vital Delta interact with blood thinners like warfarin?

Yes, MK-7 has a clinically meaningful interaction with warfarin (and other vitamin K antagonists) because it competes directly with warfarin's mechanism of inhibiting vitamin K recycling via VKORC1, the enzyme warfarin blocks. Even modest supplemental doses of MK-7 — as low as 50 mcg/day — can raise INR resistance and reduce warfarin's anticoagulant effect, potentially increasing clot risk in patients dependent on therapeutic anticoagulation. Patients on warfarin must not start MK-7 supplementation without physician approval and close INR monitoring.

### How long does it take for MK-7 supplements to show results on bone density?

In the primary 3-year MenaQ7 RCT, statistically significant improvements in vertebral bone mineral content and reductions in bone mineral density decline were observed beginning at the 1-year mark, with differences becoming more pronounced at 2 and 3 years. Changes in carboxylated osteocalcin — a functional biomarker of MK-7 activity — are detectable within 4–8 weeks of consistent supplementation at 180 mcg/day. Bone density itself changes slowly; users should not expect measurable DEXA scan improvements in fewer than 12 months of consistent supplementation alongside adequate calcium and vitamin D intake.

### What is the difference between K2Vital Delta and other forms of vitamin K2 like MK-4?

K2Vital Delta is menaquinone-7 (MK-7), which has a longer half-life in the body and superior tissue distribution compared to MK-4, allowing it to accumulate in extrahepatic tissues like bones and arteries more effectively. MK-4 is shorter-chain and more rapidly cleared, whereas MK-7's lipophilic properties enable transport via LDL, leading to enhanced bioavailability and sustained systemic effects. This makes K2Vital Delta particularly suited for comprehensive bone and vascular support.

### Is K2Vital Delta safe to take during pregnancy and breastfeeding?

While vitamin K2 is essential for fetal development and bone mineralization, pregnant and breastfeeding women should consult their healthcare provider before supplementing with K2Vital Delta, as individual circumstances and medication use vary. K2 is fat-soluble and can accumulate in tissues, making professional guidance important to determine appropriate dosing during these sensitive periods. Your doctor can assess whether dietary sources or supplementation is necessary based on your individual health profile.

### How does K2Vital Delta absorption compare when taken with meals versus on an empty stomach?

K2Vital Delta should be taken with meals containing dietary fat, as its lipophilic nature requires fat for optimal absorption and transport via LDL particles. Taking it on an empty stomach may significantly reduce bioavailability, diminishing its ability to reach bone and vascular tissues effectively. Pairing K2Vital Delta with foods containing healthy fats (olive oil, nuts, fatty fish) maximizes its physiological impact.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*